Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Sindall Group Regulatory News (MGNS)

Share Price Information for Morgan Sindall Group (MGNS)

Share Price is delayed by 15 minutes
Get Live Data
4,430.00    -16.00 (-0.36%)
Bid:
4,410.00
Ask:
4,414.00
Spread: 4.00 (0.091%)
Market Cap: £2.07b
MGNS Live PriceLast checked at - London Stock Exchange

Intraday Morgan Sindall Group Share Chart

Director/PDMR Shareholding

3 Mar 2015 07:30

RNS Number : 3213G
Morgan Sindall Group PLC
03 March 2015
Β 

ο»Ώ

MORGAN SINDALL GROUP plc

(the "Company")

Β 

Notification of Transactions by Directors

Β 

The Morgan Sindall 2014 Long Term Incentive Plan (the Plan)

Β 

Grant of conditional share awards

On 2 March 2015, certain directors of the Company were granted conditional share awards over ordinary shares of 5p each in the capital of the Company ("shares") under the Morgan Sindall 2014 Long Term Incentive Plan ("the Plan").

Β 

Details of the directors and the number of shares under conditional share awards granted to them under the Plan are set out below:

Β 

Director

Number of conditional shares awarded

John Morgan

98,680

Steve Crummett

74,348

Β 

Conditional share awards will normally vest on 2 March 2018 being the third anniversary of the date of grant, subject to continued employment with the Company and the satisfaction of the following performance conditions, which are measured over a period of three financial years ending on 31 December 2017:

Β 

Β· the number of shares under award representing 100% of the relevant director's salary will be based on the average annual growth in earnings per share ("EPS") relative to the Retail Prices Index; and

Β· the number of shares under award representing 50% of the relevant director's salary will be based on a performance condition measuring the Company's total shareholder return ("TSR") compared with eight of its UK listed peers.

Β 

Depending on whether or not the performance conditions are met the directors will receive between 0% and 100% of the award. Details of the performance conditions will be set out in the Directors' Remuneration Report in the Company's 2014 Annual Report (which will be published on or about 19 March 2015).

Β 

In the event that the Directors' Remuneration Policy for the year ended 31 December 2014 does not receive shareholder approval at the 2015 AGM, the total maximum number of shares under each award shall be adjusted downwards to 100% of salary (i.e. so that the award is made in accordance with the terms of the previous Directors' Remuneration Policy approved at the AGM on 8 May 2014). In these circumstances, the performance conditions applying to the awards shall be based 50% on the EPS condition and 50% on the TSR condition.

Β 

No consideration was paid for the grant of the awards.

Β 

Following the grant of the conditional share awards under the Plan these directors maintain the following beneficial interests in the issued share capital of the Company:

Β 

Director

Beneficial interest in the shares of the Company

% of the issued share capital of the Company

Total number of shares over which options are held

Total number of conditional share awards held

John Morgan

3,999,322

9.06

295,116

303,777

Steve Crummett

Β 12,200

Β 0.03

Β Nil

208,055

Β 

This notification relates to transactions notified in accordance with both Disclosure Rule 3.1.4R (1) (a) and Disclosure Rule 3.1.4R (1) (c).

Β 

Contact:

Β 

Clare Sheridan Tel: 020 7307 9200

Company Secretary

3 March 2015

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSLLFIAVEIFIIE
Date   Source Headline
3rd Jun 202611:56 amRNSDirector/PDMR Shareholding
1st Jun 20269:27 amRNSTotal Voting Rights
27th May 20261:29 pmRNSAdmission to Trading
20th May 202611:35 amRNSIssue of Equity
7th May 202612:38 pmRNSResult of AGM
1st May 20261:33 pmRNSDirector/PDMR Shareholding
1st May 202610:57 amRNSTotal Voting Rights
20th Apr 20263:44 pmRNSHolding(s) in Company
16th Apr 20264:09 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSTrading and Outlook for 2026
14th Apr 20262:18 pmRNSAdmission to Trading
1st Apr 20269:53 amRNSTotal Voting Rights
26th Mar 20261:27 pmRNSHolding(s) in Company
24th Mar 202612:56 pmRNSAnnual Financial Report
20th Mar 202612:42 pmRNSIssue of Equity
9th Mar 20263:35 pmRNSDirector/PDMR Shareholding
9th Mar 20263:35 pmRNSDirector/PDMR Shareholding
9th Mar 20263:30 pmRNSDirector/PDMR Shareholding
9th Mar 20263:30 pmRNSDirector/PDMR Shareholding
4th Mar 20262:38 pmRNSDirector/PDMR Shareholding
4th Mar 20262:36 pmRNSDirector/PDMR Shareholding
3rd Mar 20263:33 pmRNSIssue of Equity / Admission to Trading
2nd Mar 20269:22 amRNSTotal Voting Rights
26th Feb 20269:53 amRNSDirector Declaration
25th Feb 20267:00 amRNSResults for the Full Year ended 31 December 2025
12th Feb 20267:00 amRNSTrading and Outlook for 2026
2nd Feb 20269:13 amRNSTotal Voting Rights
19th Jan 20267:00 amRNSNotice of Full Year Results
2nd Jan 202611:09 amRNSTotal Voting Rights
16th Dec 202510:16 amRNSAdditional Listing
2nd Dec 20259:12 amRNSTotal Voting Rights
25th Nov 20254:14 pmRNSHolding(s) in Company
12th Nov 20254:07 pmRNSDirector/PDMR Shareholding
3rd Nov 202510:58 amRNSTotal Voting Rights
20th Oct 202511:24 amRNSBlock listing Interim Review
20th Oct 20259:32 amRNSDirector/PDMR Shareholding
2nd Oct 20257:00 amRNSTrading Update and Outlook for 2025
1st Oct 20259:05 amRNSTotal Voting Rights
1st Sep 20258:59 amRNSTotal Voting Rights
4th Aug 20253:09 pmRNSDirector/PDMR Shareholding
1st Aug 20257:00 amRNSTotal Voting Rights
29th Jul 20257:00 amRNSResults For the Half Year (HY) Ended 30 June 2025
18th Jul 20258:40 amRNSHolding(s) in Company
1st Jul 20259:34 amRNSTotal Voting Rights
25th Jun 20258:47 amRNSAdditional Listing
24th Jun 20257:00 amRNSNotice of Half Year Results
17th Jun 20257:00 amRNSTrading Update and Outlook for 2025
16th Jun 20251:55 pmRNSDirector/PDMR Shareholding
2nd Jun 20253:45 pmRNSTotal Voting Rights
2nd Jun 202511:14 amRNSCompany Secretary Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.